SCHEMBL29913985

SCHEMBL29913985

CCC(=O)Oc1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.50
LIPG Q9Y5X9 5/20 0.47
LPL P06858 4/20 0.47
HIF1A Q16665 5/20 0.40
ELANE P08246 1/20 0.39
ESR1 P03372 2/20 0.39
KMT2A Q03164 2/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
ROCK1 Q13464 1/20 0.37
LMNA P02545 1/20 0.36
USP2 O75604 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451076 0.84 CYP3A4 (0.50) ACHELIPGLPLHIF1AKMT2A
SCHEMBL5761327 0.83 MEN1 (0.54) LIPGLPLHIF1AKMT2ACA1
SCHEMBL28521280 0.83 ACHE (0.44) ACHELIPGLPLHIF1A
SCHEMBL28809490 0.82 LIPG (0.43) LIPGLPLHIF1AELANECA1
SCHEMBL28677051 0.81 POLB (0.47) LIPGLPLHIF1AELANEKMT2A
SCHEMBL28817131 0.81 LPL (0.45) LIPGLPL
SCHEMBL25491942 0.81 LIPG (0.41) ACHELIPGLPLHIF1AKMT2A
SCHEMBL18241283 0.81 LIPG (0.41) LIPGLPLHIF1AKMT2ACA1
SCHEMBL15639905 0.81 ACHE (0.50) ACHELIPGLPLKMT2ALMNA
SCHEMBL4045906 0.81 ELANE (0.41) LIPGLPLHIF1AELANECA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
US-12459915-B2 Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2025-11-04 US disclosed
EP-4071147-B1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEMICAL LTD (KR) 2025-03-26 EP disclosed
US-20230322706-A1 NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEM, LTD. (KR) 2023-10-12 US disclosed
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-16 US disclosed
EP-4071147-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF Lg Chem, Ltd. (KR) 2022-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF DGAT2, DGAT1, PLAAT2 ACHE 3064/4885LIPG 115/4885LPL 49/4885
US-20230322706-A1 NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF DGAT2, DGAT1, MOGAT2 ACHE 2701/4885LIPG 85/4885LPL 55/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 ACHE 3223/4885LIPG 118/4885LPL 66/4885
US-12459915-B2 Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, LCAT ACHE 2189/4885LIPG 63/4885LPL 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.